COTA Supports FDA Assessment of Real-World Data through Membership in COVID-19 Evidence Accelerator
Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.
COTA, Inc. Announces Participation in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and DIA 2020 Virtual Global Annual Meeting
COTA, Inc., is pleased to announce its involvement and participation in two industry leading conferences – the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and the DIA 2020 Virtual Global Annual Meeting. Collectively, the involvement at these two premier events further underscores the importance of RWD’s role in clinical research and oncology care delivery.
COTA, Inc. named a 2020 Fast 50 company by Boston Business Journal
The Boston Business Journal has named COTA, Inc. to its exclusive 2020 Fast 50 list, which represents the 50 fastest-growing private companies in Massachusetts.
COTA Appoints C.K. Wang, M.D. as New Chief Medical Officer
Dr. Wang’s Commitment to COTA’s Mission and Extensive Oncology Background Supports The Company’s Next Stage of Growth and Ongoing Partnerships
COTA and Guardant Health Collaborate Using Real-World Data to Reveal Insights into Metastatic Colon Cancer and Prevalence of Biomarker Testing
Research Published in JCO Precision Oncology Found Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing
COTA Presents Posters at ASH Annual Meeting, Reviewing Complexities of Generating RWD and How it Complements Traditional Clinical Trial Data
Research Presented Alongside MMRF and HUMC Evaluates Opportunity for RWE to Study Patient Treatment & Outcomes in Routine Cancer Care
Initial Results of Real-World Evidence Pilot Study Published in JCO Clinical Cancer Informatics
Friends of Cancer Research collaborative project brings together COTA and nine other healthcare organizations & stakeholders to fuel understanding of RWE in oncology
COTA, Inc. Announces Headquarter Relocation to Boston for Continued Growth
COTA is relocating our headquarters to Boston! We are excited to immerse ourselves in a city that is rich in health technology and life science industries that align with our mission of improving cancer care.
COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration
Collaboration Aims to Study Variation in Cancer Treatment Patterns by Extracting and Analyzing Real-World Data
COTA Increases Breakthrough Capability, adds Chief Technology Officer
COTA Increases Breakthrough Capability, adds Chief Technology Officer
